About
Small Molecules Targeting Cancer
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Team (31)
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
632
By Phase
PHASE2: 1PHASE1: 3PHASE1/PHASE2: 1
By Status
TERMINATED: 3RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06152042Lead Sponsor
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
PHASE2Terminated
37 participants
Started: Dec 28, 2023 · Completed: Jul 18, 2025
NCT05918692Lead Sponsor
A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
PHASE1Recruiting
84 participants
Started: Jul 26, 2023 · Completed: Dec 31, 2025
NCT05631574Lead Sponsor
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
PHASE1Terminated
13 participants
Started: Jan 12, 2023 · Completed: Jan 15, 2025
NCT05731544Lead Sponsor
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
PHASE1/PHASE2Completed
443 participants
Started: Aug 17, 2022 · Completed: Jul 8, 2025
NCT05153330Lead Sponsor
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
PHASE1Terminated
55 participants
Started: Jan 24, 2022 · Completed: May 2, 2025
Locations (1)
Headquarters
Redwood City, CA, United States
Map
Loading map...